AbbVie Inc. (ABBV) — financial distillation
Annual history (10-K)
Quarterly history (10-Q)
Two headline lines are shown to start. Click any item in a legend to add or remove it — every figure on the chart is one the table below also carries, for the period it names.
In brief, from the full filed history
- Revenue grew from $17.44B (period ending 2011-12-31) to $61.16B (period ending 2025-12-31) — a 9.4% annual pace across 14 year(s) of filed history.
- Net margin compressed from 8.9% to 6.9% over that same span.
- Across 44 tracked quarters, the strongest was $16.99B (quarter ending 2026-06-30) and the weakest was $4.17B (quarter ending 2012-03-31).
Annual — most recent 10-K
| Line | Value | Period ends | Form | Filing |
|---|---|---|---|---|
| Revenue | $61.16B | 2025-12-31 | 10-K | 0001551152-26-000008 |
| Gross profit | $12.07B | 2025-12-31 | 10-K | 0001551152-26-000008 |
| Operating income | $15.07B | 2025-12-31 | 10-K | 0001551152-26-000008 |
| Net income | $4.23B | 2025-12-31 | 10-K | 0001551152-26-000008 |
| Diluted EPS | $2.36 | 2025-12-31 | 10-K | 0001551152-26-000008 |
| Total assets | $133.96B | 2025-12-31 | 10-K | 0001551152-26-000008 |
| Cash & equivalents | $5.23B | 2025-12-31 | 10-K | 0001551152-26-000008 |
| Operating cash flow | $19.03B | 2025-12-31 | 10-K | 0001551152-26-000008 |
Quarterly — most recent 10-Q
| Line | Value | Period ends | Form | Filing |
|---|---|---|---|---|
| Revenue | $8.24B | 2018-09-30 | 10-Q | 0001551152-18-000042 |
| Operating income | $6.43B | 2026-06-30 | 10-Q | 0001551152-26-000026 |
| Net income | $3.61B | 2026-06-30 | 10-Q | 0001551152-26-000026 |
| Diluted EPS | $2.03 | 2026-06-30 | 10-Q | 0001551152-26-000026 |
| Total assets | $135.12B | 2026-06-30 | 10-Q | 0001551152-26-000026 |
| Cash & equivalents | $6.57B | 2026-06-30 | 10-Q | 0001551152-26-000026 |
| Operating cash flow | $3.83B | 2026-03-31 | 10-Q | 0001551152-26-000017 |
Reading
The figures above are taken directly from filings with the U.S. Securities and Exchange Commission. The reading below was generated by a local language model from only those figures; it introduces no numbers of its own. It is not investment advice.
AbbVie Inc.’s (ABBV) business scale is substantial, with a revenue of $61.16 billion in the most recent annual period, reflecting a 9.4% annual growth over 14 years. The company’s mix has evolved, as indicated by the net income margin compression from 8.9% to 6.9% during this period.
The multi-year revenue trajectory shows steady growth, albeit with some fluctuations. Notably, the highest quarterly revenue of $16.99 billion was reported in Q2 2026, while the lowest was $4.17 billion in Q3 2012. This trend underscores AbbVie’s ability to maintain growth despite market variations.
In the upcoming filings, investors should monitor the company’s capacity to sustain revenue growth and improve net income margins, given the historical compression trend. Additionally, the management’s strategies to optimize cash flow and maintain a robust balance sheet will be crucial indicators of AbbVie’s future financial health.
Source: SEC EDGAR company facts for CIK 0001551152 · filings index